Suspected SVC syndrome (adult)
Blocked flow in the superior vena cava. This pathway is for adults. Children with a mediastinal mass: paediatric oncology and paediatric anaesthesia.
All Pathways
Hematology & OncologyEmergency
Superior Vena Cava (SVC) Syndrome Management
Superior Vena Cava (SVC) Syndrome Management: Suspected SVC syndrome (adult) → Recognise clinical features → Life-threatening features (Yu grade 4)? → L...
Pathway Overview
18 steps
Algorithm Steps
18 total
01Start 02Action Recognise clinical features
Venous congestion of the head, neck and arms. Symptoms are often worse lying flat or bending forward.
- Face or neck swelling, fullness in the head, dyspnoea, cough
- Arm swelling; distended neck and chest wall veins; plethora or cyanosis
- Headache, dizziness or visual change; stridor or hoarseness
- Stridor, confusion, or syncope without a trigger: life-threatening
- Up to 60% have no known cancer yet: SVC syndrome can be the first sign
03Decision Life-threatening features (Yu grade 4)?
Stridor (laryngeal oedema or airway compression), confusion or obtundation (cerebral oedema), or syncope without a trigger, hypotension or renal impairment.
- Grade 4 (life-threatening): stridor; confusion or obtundation; syncope without a trigger, hypotension or renal impairment
- Grade 3 (severe): headache or dizziness; mild or moderate laryngeal oedema; syncope after bending
- Grade 1-2: head and neck oedema, with or without mild functional impairment
- If Yes
04Warning Life-threatening: mediastinal mass or airway compression can collapse the airway
Before sedation, lying flat, anaesthesia or procedures, call senior anaesthesia early.
- Keep the patient sitting up; avoid sedation, lying flat and muscle relaxants
- Keep spontaneous breathing (awake or staged technique); rigid bronchoscopy and an experienced team ready
- High risk: ECMO or bypass standby where available; prefer procedures under local anaesthesia
05Action Life-threatening: stabilise and call IR, oncology and anaesthesia now
Sit up, oxygen, secure the airway plan, then urgent endovascular stent. No diuretics if hypotensive or hypovolaemic.
- Sit upright; oxygen; IV access in a leg vein if possible (arm veins drain through the blocked SVC)
- Urgent endovascular stent (interventional radiology); CT with IV contrast first only if it can be done safely. No IR on site: urgent transfer, sitting up, with an airway plan for the transfer
- Stridor: laryngeal oedema from venous congestion improves with a stent; tumour compressing the trachea needs a separate airway plan
- Dexamethasone (adult) 16 mg oral or IV, then 8 mg twice daily; stop if no benefit, reduce gradually if it helps; give a PPI and check blood glucose. Lymphoma possible and no tissue yet: discuss with haematology first, but do not delay if the airway is threatened.
- Advanced cancer: agree goals of care early. Not for stent or cancer treatment: opioid, benzodiazepine and oxygen for breathlessness
06Action Life-threatening: endovascular SVC stent
First-line for rapid relief of symptomatic obstruction; can be done before or after the tissue diagnosis.
- Thrombus: thrombolysis or thrombectomy first. Check bleeding risk (brain metastases, recent surgery, active bleeding, low platelets); if thrombolysis is contraindicated, use mechanical thrombectomy.
- Airway at risk: senior anaesthetist plans sedation or anaesthesia for the procedure
- Fatal complications 1-2% (SVC rupture with tamponade); all complications about 8-9%
- After stent: anticoagulant or antiplatelet per IR team
- Clinical success about 97%; relief is rapid
- Does not stop later chemotherapy or radiotherapy
07Decision Malignant cause likely?
Mass, lymph nodes or known cancer on imaging: malignant. Thrombus around a line or device, fibrosing mediastinitis, goitre or post-radiation stenosis: benign.
- If Yes
08Action Malignant: get a tissue diagnosis, least invasive route first
Histology decides treatment.
- Prefer local anaesthesia: peripheral lymph node, pleural fluid cytology, EBUS or bronchoscopy, CT- or US-guided biopsy; bone marrow if a haematological cancer is likely
- Mediastinoscopy or thoracoscopy needs general anaesthesia: senior anaesthetic review first if there is a mediastinal mass
- Lymphoma possible: take tissue before steroids unless the airway is threatened
- Known cancer with clear progression: tissue may not be needed; discuss with oncology
- Stage the cancer (CT, PET) to decide curative or palliative intent
09Decision Select cancer treatment by histology and stage
Oncology multidisciplinary team. Grade 3 symptoms or slow expected response: consider a stent as well.
- SCLC / lymphoma / germ cell
10Action SCLC, lymphoma or germ cell tumour: systemic therapy first
Chemosensitive tumours respond fast, usually within 2 weeks. Stent if symptoms are severe or do not improve.
- SCLC: platinum and etoposide; add immunotherapy in extensive stage
- Lymphoma: systemic therapy; radiotherapy may consolidate
- Germ cell tumour: chemotherapy
- High-grade lymphoma (Burkitt, lymphoblastic, diffuse large cell) or bulky fast-growing tumour: assess tumour lysis risk; hydration and prophylaxis before treatment
11Decision SVC thrombus on imaging?
Tumour compression alone does not need anticoagulation. After a stent, follow the IR plan.
- If Yes
12Action SVC thrombus: therapeutic anticoagulation
Cancer-associated thrombosis. Check bleeding risk first.
- LMWH, apixaban or rivaroxaban (edoxaban outside Australia); check drug interactions with cancer therapy
- Caution: GI or genitourinary cancer (prefer LMWH), brain metastases, recent surgery. Platelets <50 x10^9/L: haematology advice on dose
- Pregnancy or breastfeeding: LMWH, not a DOAC; creatinine clearance <30 mL/min: specialist advice
- Duration: at least 6 months; longer while cancer is active or a line stays in
13Action Follow-up and monitoring
Symptom and stent surveillance.
- Recurrent symptoms: CT venography; restenosis after stent about 10%
- Re-stent or radiotherapy for recurrence
- Treat the underlying cancer
- Early palliative care involvement
14Outcome SVC syndrome managed
Continue cancer-directed or cause-directed treatment.
If No- Path rejoins step 13Shared downstream outcome
- NSCLC palliative
15Action NSCLC (palliative) or other tumours: radiotherapy
Radiation oncology sets the dose. No trial defines the best fractionation.
- NSCLC: relief in about 60% with radiotherapy or chemotherapy
- Palliative: often 3-4 Gy per fraction for 5-10 fractions
- Useful as salvage for recurrent SVC syndrome
- Stent first if symptoms are severe
- Path rejoins step 11Shared downstream outcome
- Locally advanced NSCLC
16Action Locally advanced NSCLC (curative intent): chemoradiation
Radiation oncology and medical oncology plan concurrent or sequential treatment.
- A stent can relieve symptoms while treatment is planned
- Curative-intent radiotherapy dose per current lung cancer guidelines
- Path rejoins step 11Shared downstream outcome
If No17Action Benign cause: treat the cause (vascular surgery or IR)
Catheter or device thrombosis, fibrosing mediastinitis, goitre or radiation stenosis.
- Thrombus: therapeutic anticoagulation for at least 3 months, and while a line or device stays in; check bleeding risk first; pregnancy: LMWH
- Line or device related: vascular or IR review of line or lead removal, angioplasty and stent
- Acute thrombus with severe symptoms: catheter-directed thrombolysis or thrombectomy; check bleeding contraindications first
- Goitre: thyroid and ENT surgery
- Mild symptoms: head elevation; a diuretic may help, but not if hypotensive or hypovolaemic
- Path rejoins step 13Shared downstream outcome
If No18Action Not life-threatening: CT chest with IV contrast
CT venography shows the level, the cause (mass or thrombus) and the collaterals.
- Grade 3 (severe): same-day CT, then same-day IR and oncology review for an urgent stent
- Severe kidney impairment or iodinated contrast allergy: MR venography only if the patient can lie flat safely; otherwise discuss with radiology
- Mediastinal mass on CT: tell the anaesthetist before any sedation or procedure
- Supportive: sit up, head elevated; avoid tight collars and bending; oxygen if hypoxic; opioid or benzodiazepine for breathlessness
- Path rejoins step 07Shared downstream outcome
Guideline Source
Management of malignant superior vena cava syndrome (Chow, Simone, Rimner; Ann Palliat Med 2024, narrative review; no formal society guideline exists)
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- No formal society guideline for SVC syndrome; based on reviews and expert consensus, with little RCT evidence
- Mediastinal mass: anaesthesia, sedation and lying flat can cause airway or circulatory collapse; involve senior anaesthesia early
- Stenting availability varies by hospital; transfer may be needed
- Adults only; children with a mediastinal mass need paediatric services
- Radiotherapy fractionation and post-stent antithrombotic therapy vary between centres
Contraindicated Populations
pediatric
Applicable Regions
USEUAU
AU: Edoxaban is not on the ARTG; use LMWH, apixaban or rivaroxaban. eviQ has no SVC syndrome protocol; follow local oncology and IR pathways.
Version 2Next review: 2027-09-30
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Open page
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Superior Vena Cava (SVC) Syndrome Management?
The Superior Vena Cava (SVC) Syndrome Management is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Management of malignant superior vena cava syndrome (Chow, Simone, Rimner; Ann Palliat Med 2024, narrative review; no formal society guideline exists).
What guideline is the Superior Vena Cava (SVC) Syndrome Management based on?
This algorithm is based on Management of malignant superior vena cava syndrome (Chow, Simone, Rimner; Ann Palliat Med 2024, narrative review; no formal society guideline exists) (DOI: 10.21037/apm-23-573).
What are the limitations of the Superior Vena Cava (SVC) Syndrome Management?
Known limitations include: No formal society guideline for SVC syndrome; based on reviews and expert consensus, with little RCT evidence; Mediastinal mass: anaesthesia, sedation and lying flat can cause airway or circulatory collapse; involve senior anaesthesia early; Stenting availability varies by hospital; transfer may be needed; Adults only; children with a mediastinal mass need paediatric services; Radiotherapy fractionation and post-stent antithrombotic therapy vary between centres. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Superior Vena Cava (SVC) Syndrome Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free